<?xml version="1.0" encoding="UTF-8"?>
<ref id="B14">
 <label>14.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Le</surname>
    <given-names>TT</given-names>
   </name>, 
   <name name-style="western">
    <surname>Andreadakis</surname>
    <given-names>Z</given-names>
   </name>, 
   <name name-style="western">
    <surname>Kumar</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Román</surname>
    <given-names>RG</given-names>
   </name>, 
   <name name-style="western">
    <surname>Tollefsen</surname>
    <given-names>S</given-names>
   </name>, 
   <name name-style="western">
    <surname>Saville</surname>
    <given-names>M</given-names>
   </name>, 
   <name name-style="western">
    <surname>Mayhew</surname>
    <given-names>S</given-names>
   </name>
  </person-group>
  <year>2020</year>
  <article-title>The COVID-19 vaccine development landscape</article-title>. 
  <source>Nat Rev Drug Discov</source>
  <volume>19</volume>:
  <fpage>305</fpage>−
  <lpage>306</lpage>. doi:
  <pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id>.
  <pub-id pub-id-type="pmid">32273591</pub-id>
 </mixed-citation>
</ref>
